April 14, 2026 4:41pm

The market's resilience is noteworthy given the war-footing backdrop. Wholesale inflation stands at a 3-year high, oil prices are elevated by geopolitical conflict, while some are issuing global recession warnings as the U.S. could practice avoidance

Even while climbing the wall of worry

Reiterating, C&GT equities are STILL under a microscope during these times re their fair value until it’s clear that there is an end of the Iranian conflict

Never say never, there could be a re-escalation and more downside from here; “uncle algo and his electronic trading dwarfs” are hungry

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: None, not changing view from Monday

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Tuesday: The Dow closed UP +317.56 points or +0.60%, the S&P closed UP +81.15 points or +1.18% while the Nasdaq closed UP +455.347 points or +1.96%

  • Theme of the session: traders shrugged off a breakdown in peace talks and optimistic that a deal is still possible.

Tueday (my) 40-company covered sector’s advance/decline line opened positive with 30 incliners, 2 decliners and 2 flats, ending with a positive close of 32 incliner, 6 decliners and 2 flats

  • Waiting for the 1st strike of Military operation

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The PPI a gauge of demand goods and services, increased a seasonally adjusted 0.5% for the month, well below the consensus estimate for 1.1%.  Excluding food and energy, core PPI was up just 0.1% against the forecast for 0.5%.

The CBOE Fear (VIX) index, Tuesday closed at 18.47, after Monday’s 19.33, Friday’s 19.30, Thursday’s 19.57, Wednesday’s 21.03, Tuesday’s 25.92, and last Monday’s 24.16

Metrics: Tuesday …

  • The RUT was up +34.08 points or +1.28%,
  • The XLV was up +0.81 points or +0.55%,
  • The NBI was up +118.25 points or +1.99%;
  • The XBI was up +3.75 points or +2.84%
  • The IWM was up +3.64 or +1.37%;
  • The IBB was up +3.66 points or +2.13%,
  • The VIX was down -0.65 points or -3.40% at to 18.47

 

Q2/26 – 1 holiday, 1 neutral, 2 negative and 5 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Tuesday Closing UP (10 of 32) 

  • Alnylam Pharmaceuticals (ALNY +$6.41 after Monday’s +$10.89 after Friday’s +$0.83),
  • Vertex (VRTX +$4.23 after Monday’s +$3.61 after Friday’s -$10.47),
  • IQVA Holdings (IQV +$3.23 after Monday’s +$4.63 after Friday’s -$1.66),
  • Arrowhead Pharmaceuticals (ARWR +$2.90),
  • Moderna (MRNA +$2.16 after Monday’s -$0.28)
  • CRISPR Therapeutics (CRSP +$2.03 after Monday’s +$3.78),
  • Ionis Pharmaceuticals (IONS +$1.81 after Monday’s -$0.22 after Friday’s -$1.26),
  • BioNTech (BNTX +$1.71 after Monday’s +$1.51 after Friday’s +$3.52),
  • AxoGen (AXGN +$0.99 after Monday’s +$1.20 after Friday’s -$1.06),
  • Ultragenyx Pharmaceuticals RARE +$0.94),

Flat (2)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus TR (OTCQB: HRGN),

Tuesday’s Closing DOWN (6 of 6): 

  • uniQure NV (QURE -$0.83 after Monday’s +$2,54 after Friday’s -$0.92),
  • Precigen (PGEN -$0.21),
  • Solid Biosciences (SLDB -$0.16),
  • Cellectis SA (CLLS -$0.12),
  • Mesoblast (MESO -$0.09 after Monday’s -$0.30 after Friday’s +$0.45),
  • Sangamo Therapeutics (SGMO -$0.0012)

 

The Bottom Line: More of the … WHY and a lot of what ifs …

Indexes remained firmly in the green Tuesday as investors ... seemed relieved by lower inflation data.

  • The PPI, Producer price index rose in March but considerably less than expected as the Iran war’s push on energy prices rekindled fears of another inflation burst.
  • The Magnificent 7 group is leading the charge for the cap-weighted indexes. Alphabet (NASDAQ: GOOG) (GOOGL), Nvidia (NVDA), and Amazon (AMZN) are doing the heavy lifting with the richest combinations of index weights and single-day gains.
  • Their moves simply make a bigger difference to the Nasdaq-100 index, since the seven stocks carry a total weight of 65% there but only 38% on the S&P 500. <Motley Fool>

 

April 3rd Week:

  • 4/14 - Tuesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 4/13 - Monday closed positive with 33 incliners, 5 decliners and 2 flats

April – 2nd Week

  • 4/10 - Friday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/9 - Thursday closed positive with 24 incliners, 13 decliners and 3 flats
  • 4/8 – Wednesday closed positive with 27 incliners, 8 decliners and 5 flats
  • 4/7 – Tuesday closed negative with 15 incliners, 21 decliners and 4 flats
  • 4/6 - Monday closed positive with 20 incliners, 18 decliners and 2 flats

April – 1st week

  • 4/2 - Thursday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 4/1 – Wednesday closed positive with 29 incliners, 8 decliners and 3 flats

 

Q1/26 Earnings Release Dates:

  • AxoGen (AXGN) – Tuesday, 4/28

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)
  • Monday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)
  • Friday: BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY) and Beam Therapeutics (BEAM)

The worst three (3) in the session: Losers

  • Tuesday: uniQure NV (QURE), Precigen (PGEN) and Solid Biosciences (SLDB)
  • Monday: Arrowhead Pharmaceuticals (ARWR), Supernus Therapeutics (SUPN) and Ionis Pharmaceuticals (IONS)
  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Ionis Pharmaceuticals (IONS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.